CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
published in: Journal of Clinical Oncology
date of publication: 2015-01-20
language: English
main subject: trastuzumab, capecitabine
Cites articles
There is nothing here
Article - wd:Q55068564